Skip to main content
OpenTrials
Completed

NCT Number: NCT06652035

Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies

Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperuricemia Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dr. Buccomino Medical Clinic

Milan, Italy

About this study

In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults
  • BMI between 18.5 and 29.9 kg/m²
  • Non-smoker
  • Consumtion of less than 3 units of alcohol per day

Exclusion criteria

  • - Plasma uric acid concentrations above 7 mg/dL
  • Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones

Treatment and study plan

Quevir® (Quercetin Phytosome®)

Dietary Supplement

500 mg Quevir® (Quercetin Phytosome®) tablet

Other names: Quevir®

Bactoblis®

Dietary Supplement

Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)

Primary outcomes

  1. Change in plasma uric acid level

    Time frame: 90 days

    Supplement effect on plasma uric acid level

Secondary outcomes

  1. Change in plasma cholesterol level

    Time frame: 90 days

    Supplement effect on plasma cholesterol level

  2. Change in plasma triglycerides level

    Time frame: 90 days

    Supplement effect on plasma triglycerides level

  3. Change in plasma glucose level

    Time frame: 90 days

    Supplement effect on plasma glucose level

  4. Change in plasma insulin level

    Time frame: 90 days

    Supplement effect on plasma insulin level

  5. Change in plasma creatine phosphokinase level

    Time frame: 90 days

    Supplement effect on plasma creatine phosphokinase level

  6. Change in alanine transaminase level

    Time frame: 90 days

    Supplement effect on liver function

  7. Change in aspartate aminotransferase level

    Time frame: 90 days

    Supplement effect on liver function

  8. Change in alkaline phosphatase level

    Time frame: 90 days

    Supplement effect on liver function

  9. Change in gamma-glutamyl transferase level

    Time frame: 90 days

    Supplement effect on liver function

  10. Change in bilirubin level

    Time frame: 90 days

    Supplement effect on liver function

  11. Incidence of side effects

    Time frame: 90 days

    Number of patients reporting side effects

Sponsors and collaborators

Lead sponsor

Liaquat University of Medical & Health Sciences

Other

Collaborators

  • The University of Urbino Carlo Bo, Italy

Registry information

Official study title

Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Oct 22, 2024
Registry last updated
Oct 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.